Abstract | BACKGROUND: STUDY DESIGN: Two hundred two node-positive breast cancer patients were prospectively accrued and treated with standardized treatment and surveillance protocol. Tumor eIF4E protein level was quantified by Western blots as x-fold over benign samples from noncancer patients. Primary end point was systemic metastasis. RESULTS: Systemic recurrence was detected in 22.2% of the low eIF4E group, 27.3% of the intermediate group, and 49% of the high group, at a median follow-up of 47 months. A greater risk for systemic metastasis was seen in the high eIF4E group compared with the low group (log-rank test, p = 0.0084). Patients in the high eIF4E group had a 1.5-fold (hazard ratio = 1.52; 95% CI, 1.07-2.17; p = 0.0206) higher risk for systemic metastasis than the low group. Sixty percent of the patients with high eIF4E were observed to have metastasis to multiple sites, compared with 50% in the intermediate group, and 14.5% in the low group (p = 0.02, Fisher's exact test). When patients were segregated based on nodal classification (N1, N2, and N3), eIF4E overexpression continued to be a predictor for systemic dissemination in patients with N1 disease. CONCLUSIONS: High eIF4E is correlated with an increased risk for systemic metastasis in node-positive breast cancer patients. High eIF4E overexpression was associated with a higher incidence of metastasis to multiple sites. Therefore, high eIF4E overexpression appears to be a marker for molecular events that increases risk for systemic dissemination.
|
Authors | Xuedong Yin, Roger H Kim, Guang Sun, Janet K Miller, Benjamin D Li |
Journal | Journal of the American College of Surgeons
(J Am Coll Surg)
Vol. 218
Issue 4
Pg. 663-71
(Apr 2014)
ISSN: 1879-1190 [Electronic] United States |
PMID | 24491247
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014 American College of Surgeons. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Eukaryotic Initiation Factor-4E
|
Topics |
- Biomarkers, Tumor
(metabolism)
- Blotting, Western
- Breast Neoplasms
(metabolism, mortality, pathology, therapy)
- Combined Modality Therapy
- Eukaryotic Initiation Factor-4E
(metabolism)
- Female
- Follow-Up Studies
- Humans
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Prospective Studies
- Risk
- Survival Analysis
|